Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia

Diego A. Pereira-Martins, Juan L. Coelho-Silva, Isabel Weinhäuser, Pedro L. Franca-Neto, Douglas R. Silveira, César Ortiz, Amanda Moreira-Aguiar, Marinus M. Lima, Luisa C. Koury, Raul A. de Melo, Ana B. Glória, Evandro M Fagundes, Bruno K. Lino, Katia Pagnano, Rosane Bittencourt, Elenaide Nunes, Fabiola Traina, Lorena Figueiredo-Pontes, Armand Keating, Martin S. TallmanRaul C. Ribeiro, Richard Dilon, Arnold Ganser, Miguel A. Sanz, Nancy Berliner, Peter Valk, Bob Löwenberg, Tiziana Ottone, Nelida I. Noguera, Maria T. Voso, Francesca Paoloni, Paola Fazi, Emanuele Ammatuna, Gerwin Huls, Jan Jacob Schuringa, Eduardo M. Rego, Antonio R. Lucena-Araujo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.

Original languageEnglish (US)
Pages (from-to)170-174
Number of pages5
JournalBritish Journal of Haematology
Issue number2
StatePublished - Jan 2023


  • ATRA
  • anthracycline-based chemotherapy
  • mtDNA content
  • oxidative phosphorylation

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia'. Together they form a unique fingerprint.

Cite this